Background and Aims: An HCV cure is now possible in a large proportion of HIV-HCV patient. We present real life results of a compassionate use program promoted by SIMIT (Infectious and Tropical Diseases Italian Society) of Dasabuvir and Ombitasvir/Paritaprevir/Ritonavir ± Ribavirin for 12 weeks in 213 HIV-HCV genotype 1 patients. Data on efficacy and tolerability of this strategy in HIV patients have been reported until now only in 43 non cirrhotic HIV subjects.
Dasabuvir and Ombitasvir/Paritaprevir/Ritonavir with or without Ribavirin in Patients with HIV-HCV Coinfection. Real Life Interim Analysis of an Italian Multicentre Compassionate Use Program / Teti, E.; Ricciardi, A.; Antinori, A.; Galli, M.; Rizzardini, G.; Di Biagio, A.; Angarano, G.; Bruno, R.; Mussini, C.; De Luca, A.; Cattelan, A.; Lazzarin, A.; Taliani, G.; D’Arminio Monforte, A.; Mastroianni, C. M.; Di Perri, G.; Maggiolo, F.; Puoti, M.; Castelli, F.; Gori, A.; Boffa, N.; Cacopardo, B.; Giacometti, A.; Parruti, G.; Vullo, V.; Chirianni, A.; Pennica, A.; Pasquazzi, C.; Sighinolgi, L.; Gentilotti, E.; Sarmati, L.; Andreoni, M.. - In: JOURNAL OF HEPATOLOGY. - ISSN 0168-8278. - STAMPA. - 64:Suppl 2(2016), pp. S763-S763. (Intervento presentato al convegno EASL International Liver Congress tenutosi a Barcelona, SPAIN nel APR 13-17, 2016) [10.1016/S0168-8278(16)01487-2].
Dasabuvir and Ombitasvir/Paritaprevir/Ritonavir with or without Ribavirin in Patients with HIV-HCV Coinfection. Real Life Interim Analysis of an Italian Multicentre Compassionate Use Program
Taliani, G.;Mastroianni, C. M.;Vullo, V.;Pennica, A.;Pasquazzi, C.;
2016
Abstract
Background and Aims: An HCV cure is now possible in a large proportion of HIV-HCV patient. We present real life results of a compassionate use program promoted by SIMIT (Infectious and Tropical Diseases Italian Society) of Dasabuvir and Ombitasvir/Paritaprevir/Ritonavir ± Ribavirin for 12 weeks in 213 HIV-HCV genotype 1 patients. Data on efficacy and tolerability of this strategy in HIV patients have been reported until now only in 43 non cirrhotic HIV subjects.| File | Dimensione | Formato | |
|---|---|---|---|
|
Teti_Dasabuvir_2016.pdf
accesso aperto
Tipologia:
Documento in Post-print (versione successiva alla peer review e accettata per la pubblicazione)
Licenza:
Tutti i diritti riservati (All rights reserved)
Dimensione
51.96 kB
Formato
Adobe PDF
|
51.96 kB | Adobe PDF |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
